Chosa Oncology AB has announced new results demonstrating that its Platin-DRP® biomarker robustly predicts overall survival in lung cancer patients treated with platinum-based chemotherapy. The findings, based on NanoString data, build upon previous results from the ETOP/EORTC SPLENDOUR study, which utilized the Affymetrix assay platform. The NanoString analysis confirmed a high correlation with the original Platin-DRP® signature and showed that higher Platin-DRP® scores significantly predicted longer overall survival in both carboplatin-treated and overall platinum-treated populations. These results have already been presented by the company. Chosa Oncology AB is currently engaged in regulatory discussions and preparing for commercialization, including further analytical validation and collaboration with international lung cancer experts. The company is also exploring the predictive potential of the Cisplatin-DRP in patients treated with both cisplatin and carboplatin, with plans for future research to assess its utility in combination with PD-1/L1 inhibitors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 20251211:BIT:3845:0) on December 11, 2025, and is solely responsible for the information contained therein.
Comments